• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Edgewise Therapeutics Inc.

    4/23/26 4:07:02 PM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EWTX alert in real time by email
    DEFA14A 1 ewtx-20260423xdefa14a.htm DEFA14A

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549


    SCHEDULE 14A


    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934

    (Amendment No.   )

    ​

    ​

    Filed by the Registrant     ⌧

    Filed by a party other than the Registrant ☐

    ​

    ​

    Filed by a Party other than the Registrant      

    ​

    ​

    Check the appropriate box:

    ​

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☒

    Definitive Proxy Statement

    ☐

    Definitive Additional Materials

    ☐

    Soliciting Material under §240.14a-12

    ​

    EDGEWISE THERAPEUTICS, INC.

    (Name of Registrant as Specified In Its Charter)

    ​

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    ​

    Payment of Filing Fee (Check the appropriate box):

    ⌧

    No fee required.

    ☐

    Fee paid previously with preliminary materials.

    ​

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

    ​

    ​

    ​

    ​

    ​

    ​


    GRAPHIC

    Your Vote Counts! Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V95012-P52029 *Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares. EDGEWISE THERAPEUTICS, INC. ATTENTION: SECRETARY 1715 38TH STREET BOULDER, COLORADO 80301 EDGEWISE THERAPEUTICS, INC. 2026 Annual Meeting Vote by June 3, 2026 11:59 PM ET You invested in EDGEWISE THERAPEUTICS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 4, 2026. Get informed before you vote View the Notice and Proxy Statement and Annual Report on Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 21, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. Vote in Person at the Meeting* June 4, 2026 10:00 am MT Vote by Internet, telephone or mail as indicated on your proxy card 1715 38th Street Boulder, Colorado 80301

    GRAPHIC

    Vote at www.ProxyVote.com V95012-P52029 Voting Items Board Recommends Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. THIS IS NOT A VOTABLE BALLOT This communication is not a form for voting and presents only an overview of the more complete proxy materials, which contain important information and are available to you on the Internet or by mail. We encourage you to access and review the proxy materials before voting. 1. Elect the directors named in the attached Proxy Statement to serve until the 2029 Annual Meeting of Stockholders. For Nominees: 01) Laura Brege 02) Badreddin Edris, Ph.D. 03) Jonathan Root, M.D. 2. Ratify the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. For 3. Conduct an advisory vote on the compensation of our named executive officers. For NOTE: In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting or any adjournment thereof.

    Get the next $EWTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EWTX

    DatePrice TargetRatingAnalyst
    9/25/2025$20.00Neutral
    Goldman
    7/30/2025$46.00Strong Buy
    Raymond James
    6/30/2025$42.00Buy
    H.C. Wainwright
    4/30/2025$41.00Buy
    Guggenheim
    4/2/2025$14.00Sector Outperform → Sector Perform
    Scotiabank
    3/7/2025$50.00Sector Outperform
    Scotiabank
    1/22/2025$30.00Hold
    Stifel
    11/22/2024$45.00Outperform
    Evercore ISI
    More analyst ratings

    $EWTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

    BOULDER, Colo., April 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on March 31, 2026, Edgewise granted inducement stock options to purchase a total of 72,000 shares of Edgewise's common stock to 4 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan"). Each

    4/1/26 8:00:00 AM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up

    –The MESA data show stabilization of function in participants on sevasemten versus the predicted functional decline observed in Becker natural history studies –– Data reinforce prior clinical findings of sevasemten in Becker, a rare disease with no approved treatments ––The GRAND CANYON placebo-controlled pivotal cohort is on track to readout in 4Q 2026 –BOULDER, Colo., March 10, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today presented at the 2026 MDA Clinical and Scientific Conference, long-term data from its MESA open-label extension study of sevasemten in Becker muscular dystrophy (Becker), a devastating genetic di

    3/10/26 7:00:00 AM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026

    BOULDER, Colo., March 4, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced that Edgewise leadership will present at the Leerink Global Healthcare Conference on Wednesday, March 11, 2026, at 1:40 p.m. ET. The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay for a limited time following the conference. It is recommended that users connect to the live webcast several minutes prior to the start to ensure

    3/4/26 8:00:00 AM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EWTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on Edgewise Therapeutics with a new price target

    Goldman initiated coverage of Edgewise Therapeutics with a rating of Neutral and set a new price target of $20.00

    9/25/25 8:29:56 AM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James initiated coverage on Edgewise Therapeutics with a new price target

    Raymond James initiated coverage of Edgewise Therapeutics with a rating of Strong Buy and set a new price target of $46.00

    7/30/25 7:32:57 AM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Edgewise Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Edgewise Therapeutics with a rating of Buy and set a new price target of $42.00

    6/30/25 8:01:12 AM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EWTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $EWTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $EWTX
    SEC Filings

    View All

    Director Fox Jonathan C bought $199,403 worth of shares (10,700 units at $18.64), increasing direct ownership by 82% to 23,702 units (SEC Form 4)

    4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

    11/13/25 6:04:59 PM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Thompson Peter A. bought $10,000,000 worth of shares (496,771 units at $20.13) (SEC Form 4)

    4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

    4/4/25 7:42:30 PM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Orbimed Advisors Llc bought $10,000,000 worth of shares (496,771 units at $20.13) (SEC Form 4)

    4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

    4/4/25 7:33:31 PM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Fox Jonathan C

    4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

    4/3/26 2:12:09 PM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Donovan Joanne M.

    4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

    4/2/26 1:01:22 PM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Donovan Joanne M.

    4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

    3/31/26 7:33:50 PM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Edgewise Therapeutics Inc.

    DEFA14A - Edgewise Therapeutics, Inc. (0001710072) (Filer)

    4/23/26 4:07:02 PM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Edgewise Therapeutics Inc.

    DEF 14A - Edgewise Therapeutics, Inc. (0001710072) (Filer)

    4/23/26 4:06:20 PM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Edgewise Therapeutics Inc.

    144 - Edgewise Therapeutics, Inc. (0001710072) (Subject)

    3/27/26 4:41:21 PM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EWTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Edgewise Therapeutics Inc.

    SC 13G/A - Edgewise Therapeutics, Inc. (0001710072) (Subject)

    11/14/24 6:22:11 PM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Edgewise Therapeutics Inc.

    SC 13G/A - Edgewise Therapeutics, Inc. (0001710072) (Subject)

    11/14/24 4:31:39 PM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Edgewise Therapeutics Inc.

    SC 13G - Edgewise Therapeutics, Inc. (0001710072) (Subject)

    11/14/24 4:14:38 PM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EWTX
    Leadership Updates

    Live Leadership Updates

    View All

    Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors

    BOULDER, Colo., Nov. 20, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology veteran Christopher Martin to its Board of Directors. Mr. Martin brings proven success across all key commercial functions, including marketing, sales, commercial operations, market access, trade and business development. "We are thrilled to welcome Chris to our Board of Directors," said Kevin Koch, Ph.D., President and Chief Executive Officer. "His commercial expertise and launch leadersh

    11/20/25 8:00:00 AM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers

    BOULDER, Colo., Nov. 10, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced the appointment of Michael Nofi, as Chief Financial Officer (CFO), effective November 10, 2025. Mr. Nofi joins Edgewise after serving as Chief Accounting Officer (CAO) at SpringWorks Therapeutics, Inc. Mr. Nofi will succeed Edgewise CFO, R. Michael Carruthers, who is retiring. "As we enter a pivotal stage in our Company's evolution, we a

    11/10/25 8:00:00 AM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors

    Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology industry veteran Arlene Morris to its Board of Directors. Ms. Morris has extensive experience in the pharmaceutical and biotechnology industries serving in numerous executive management and board roles. "With over 30 years of exceptional leadership experience in the biotech industry, we are delighted to welcome Arlene to our Board," said Kevin Koch, Ph.D., President and Chief Executive Officer. "Arlene brings invaluable expertise in strategic development and operational excellence, and we are thankful to count her as a valued advisor as we contin

    5/7/24 8:00:00 AM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EWTX
    Financials

    Live finance-specific insights

    View All

    Edgewise Therapeutics Announces Positive 4-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

    – Remarkable North Star Ambulatory Assessment scale (NSAA) improvements relative to BMD natural history trajectories – – Significant decrease in levels of serum creatine kinase (CK) and fast skeletal muscle troponin I (TNNI2), enzyme biomarkers strongly associated with muscle damage caused by BMD – – EDG-5506 continues to be well-tolerated with no serious adverse events observed – – Management hosting webcast to discuss findings on September 12 at 8:30 a.m. Eastern Time – Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today pos

    9/11/22 5:00:00 PM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Edgewise Therapeutics Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

    – EDG-5506 treatment significantly lowered muscle damage biomarkers in adults with BMD – – BMD patients were more active during 2 months of dosing with EDG-5506 relative to activity measured in BMD patients in the Phase 1 study – – EDG-5506 was well tolerated with no serious adverse events observed; safety profile supported dose escalation to 15 mg daily for all patients – – Management hosting webcast to discuss findings on June 21 at 9:00 a.m. Eastern Time – Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today positive 2-month

    6/20/22 8:00:00 AM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New 2-Month Interim Data from the ARCH Open Label Study of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) to be Presented at the Upcoming New Directions in Biology and Disease of Skeletal Muscle Conference

    - Edgewise management to host webcast conference call on Tuesday, June 21, 2022 at 9 a.m. Eastern Time - - Additional presentations and posters featuring EDG-5506 to be featured at the New Directions Conference and the upcoming PPMD Annual Conference - Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, today announced that new 2-month interim data from the ARCH open label study of EDG-5506 in individuals with BMD will be presented at the 2022 New Directions in Biology and Disease of Skeletal Muscle Conference, being held June 20-23, 2022. Edgewise ARCH Interi

    6/16/22 8:00:00 AM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care